Mnta, Genz, & Pwrm.ob: Biotech Stocks: Onyx, Genzyme, Momenta In Spotlight

Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals Inc. (MNTA)

Recent News: Biotech Stocks: Onyx, Genzyme, Momenta in spotlight

On Friday, Momenta Pharmaceutucals, a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application (ANDA) for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox(R), which is marketed by Sanofi-Aventis.

About MNTA:

Its product candidates include M-Enoxaparin, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate. Momenta Pharmaceuticals has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc.

http://www.momentapharma.com

_________________________________

Recent News: Sanofi-Aventis's Biotech Play for Genzyme

Genzyme Corporation (NASDAQ: GENZ) announced that it has entered into an agreement with Goldman, Sachs & Co. to repurchase $1 billion of Genzyme common stock under an accelerated stock repurchase program. Proceeds from its recently concluded debt offering will be used to support this first tranche of Genzymes overall $2 billion share repurchase plan announced in May.

Genzyme Corporation is one of the worlds leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

For more information visit: www.genzyme.com

_________________________________

POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

PWRM is now available for $0.0321 cents a share.Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:

Processes - The manner in which the discoveries are made and tests developed

Discoveries - Protein disease footprints,

Products - Early detection tests, Biomarkers, and Drug Targets

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.

Continue your research at www.power3medical.com

*******************************************

Sign-Up For Free Stock Alerts At http://crwepicks.com/signup

*******************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************

by: Blayne Sheffield

POST COMMENT

Set The Trends In The Rock And Republic Brand Build Stakeholder Accountability and Manage Expectations of Officials and Volunteers Warming Up And Cooling Down On Treadmills How To Fish And Conserve At The Same Time How To Choose A Trustworthy Stockbroker Ensure Your Best Renting Experience With Caution And Common Sense Diversifying Your Investments With Mutual Funds Unique And Intriguing Gadgets For Men CPT coding: For ‘above and beyond' care, report 99050 Unique And Special Anniversary Gift Ideas Dog Cages - Or Kennels, Crates And Boxes - What's The Difference? Metal Beds And The Victorian Look Mutual Fund Research: A method for choosing the right funds